Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Novartis : KHCC, Novartis Pharma AG sign cooperation agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2017 | 03:51pm CEST

Oct. 04--AMMAN -- HRH Princess Ghida Talal, the chairperson of the King Hussein Cancer Foundation's board of trustees, on Tuesday signed a memorandum of understanding (MoU) with the CEO of Novartis Pharma AG, Bruno Strigini, the Jordanian News Agency, Petra, reported.

The memorandum aims at enhancing cooperation between the two corporations in scientific research."Research is considered a vital and integrated part at [KHCC] to improve the diagnostic and treatment process of cancer patients, which is in-line with the centre's efforts that is aimed towards saving our patients," Princess Ghida said.

The memorandum was signed in the presence of Asem Mansour, director general of KHCC and Hekmat Abdul Razzaq, deputy director general of KHCC.


(c)2017 the Jordan Times (Amman, Jordan)

Visit the Jordan Times (Amman, Jordan) at www.jordantimes.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
10/19 NOVARTIS : Recent Findings from Novartis Provide New Insights into Glucosyltrans..
10/19 GILEAD SCIENCES : 2nd gene therapy for blood cancer approved
10/19 NOVARTIS : Drug Revolade(R) Shows Long-Term Disease Control for Chronic/Persiste..
10/19 NOVARTIS : sheds generics plant and 450 jobs amid pricing pressure
10/19 NOVARTIS : FDA OKs 2nd gene therapy for blood cancer; 1st for adults
10/18 NOVARTIS : 450 jobs to go as pricing pressures push Novartis to close CO generic..
10/18 NOVARTIS : drug Revolade® shows long-term disease control for chronic/persistent..
10/13 NOVARTIS : Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoretinal ..
10/13 NOVARTIS : 65-- Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoret..
10/13 NOVARTIS AG (ADR)(NYSE : NVS) Says It Will Not Sell Its Stake In Roche
More news
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 BIOTECH FORUM DAILY DIGEST : Spotlighting Ignyta's Big Recent Rally
10/19 What 'Yes' For Its CAR-T Therapy May Mean For Gilead
10/19 YOUR DAILY PHARMA SCOOP : Gilead's Brave New World, AZN's Lynparza SNDA, RXDX En..
10/19 FDA Approval Of Gilead CAR-T Therapy Will Move The Needle
Financials ($)
Sales 2017 48 864 M
EBIT 2017 11 614 M
Net income 2017 7 295 M
Debt 2017 17 700 M
Yield 2017 3,32%
P/E ratio 2017 24,53
P/E ratio 2018 21,59
EV / Sales 2017 5,00x
EV / Sales 2018 4,78x
Capitalization 226 B
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 1,9%
EPS Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.50%226 404
JOHNSON & JOHNSON23.60%382 202
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
AMGEN27.41%133 501